Filtered By:
Condition: Myeloproliferative Disorders
Therapy: Stem Cell Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 746 results found since Jan 2013.
Cernunnos deficiency: Further delineation in 5 Egyptian patients
In conclusion, Cernunnos deficiency can have a wide range of clinical features. The characteristic immune profile including a decrease in recent thymic emigrants and naive T cells, markedly elevated memory T cells together with normal to high IgM, and a decrease in IgG and IgA. This immune profile is highly suggestive of Cernunnos deficiency in T-B-NK + SCID patients especially surviving for older ages.PMID:37703920 | DOI:10.1016/j.ejmg.2023.104840
Source: European Journal of Medical Genetics - September 13, 2023 Category: Genetics & Stem Cells Authors: Rabab El Hawary Safa Meshaal Sohilla Lotfy Dalia Abd Elaziz Radwa Alkady Alia Eldash Aya Erfan Engy Chohayeb Mai Saad Rania Darwish Jeannette Boutros Nermeen Galal Aisha Elmarsafy Source Type: research
Generation of CHOPi-008-B, a euploid iPSC line from a patient with Trisomy 21 and a GATA1 mutation
Stem Cell Res. 2023 Sep 1;72:103198. doi: 10.1016/j.scr.2023.103198. Online ahead of print.ABSTRACTTransient myeloproliferative disorder (TMD) is a pre-leukemic condition that occurs only in neonates with Trisomy 21 (T21), and is attributed to a genetic interaction between the third copy of chromosome 21 (HSA21) and a mutation in the transcription factor GATA1 that results in a truncated protein (GATA1s). We generated a euploid iPSC line with a GATA1s mutation that is isogenic to a previously published pair of T21 lines with and without a GATA1 mutation. The line was characterized for pluripotency, differentiation potentia...
Source: Cell Research - September 7, 2023 Category: Cytology Authors: Kaoru Takasaki Sara S Kumar Alyssa Gagne Deborah L French Stella T Chou Source Type: research
Current therapies for classic myeloproliferative neoplasms: A focus on pathophysiology and supportive care
CONCLUSION: Treatment options for MPNs span a wide range of disease mechanisms. The growth of targeted therapies holds promise for expanding the treatment arsenal for these rare, yet complex diseases and creates opportunities to optimize supportive care for affected patients.PMID:37556726 | DOI:10.1093/ajhp/zxad181
Source: American Journal of Health-System Pharmacy : AJHP - August 9, 2023 Category: Drugs & Pharmacology Authors: Clement Chung Source Type: research
Application of Fourier Transform InfraRed spectroscopy of machine learning with Support Vector Machine and principal components analysis to detect biochemical changes in dried serum of patients with primary myelofibrosis
Biochim Biophys Acta Gen Subj. 2023 Jul 27:130438. doi: 10.1016/j.bbagen.2023.130438. Online ahead of print.ABSTRACTPrimary myelofibrosis (PM) is a myeloproliferative neoplasm characterized by stem cell-derived clonal neoplasms. Several factors are involved in diagnosing PM, including physical examination, peripheral blood findings, bone marrow morphology, cytogenetics, and molecular markers. Commonly gene mutations are used. Also, these gene mutations exist in other diseases, such as polycythemia vera and essential thrombocythemia. Hence, understanding the molecular mechanism and finding disease-related biomarker characte...
Source: Biochimica et Biophysica Acta - July 29, 2023 Category: Biochemistry Authors: Zozan Guleken Zeynep Ceylan Aynur Aday Ay şe Gül Bayrak İpek Yönal Hindilerden Meliha Nal çacı Pawe ł Jakubczyk Dorota Jakubczyk Joanna Depciuch Source Type: research
Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with < em > ASXL1 < /em > and < em > EZH2 < /em > gene mutations: A case report
CONCLUSION: During the treatment and observation of CMML and be vigilant of the growth of multiple primary malignant tumors.PMID:37383892 | PMC:PMC10294182 | DOI:10.12998/wjcc.v11.i15.3643
Source: Clinical Lung Cancer - June 29, 2023 Category: Cancer & Oncology Authors: Lai-Jun Deng Yang Dong Mi-Mi Li Chang-Gang Sun Source Type: research
Effect of hypoxia on HIF-1 α and NOS3 expressions in CD34 < sup > + < /sup > cells of JAK2V617F-positive myeloproliferative neoplasms
CONCLUSION: JAK2V617F might have specific role in HIF-1α and NOS3 regulations with respect to low oxygen concentrations in Ph- MPN. Further evaluations might reveal the effect of JAK2V617F on Ph- MPN pathogenesis in bone marrow microenvironment.PMID:37075583 | DOI:10.1016/j.advms.2023.03.003
Source: Advances in Medical Sciences - April 19, 2023 Category: Biomedical Science Authors: Can Veysel Şoroğlu İldeniz Uslu-Bıçak Selin Fulya Toprak Akif Selim Yavuz Sel çuk Sözer Source Type: research
